» Articles » PMID: 10981134

Gene Therapy of Hypertensive Vascular Injury

Overview
Date 2000 Sep 12
PMID 10981134
Authors
Affiliations
Soon will be listed here.
Abstract

Hypertension and vascular injury usually require prolonged treatment, and compliance is a key to efficacy for pharmacologically-based antihypertensive therapy. Gene therapy has the potential to be long lasting, with few side effects. Recent studies have provided promising results, in which hypertension can be treated by either augmentation of vasodilation or inhibition of vasoconstriction through gene transfer in experimental models. Gene transfer is also becoming useful for the study of mechanisms of physiologic and pathophysiologic conditions, including hypertension. In this mini-review, we summarize some recent studies in this area of research, and suggest some areas where progress is needed to advance the research toward gene therapy.

References
1.
Lin K, Chao L, Chao J . Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery. Hypertension. 1997; 30(3 Pt 1):307-13. DOI: 10.1161/01.hyp.30.3.307. View

2.
Phillips M, Wielbo D, Gyurko R . Antisense inhibition of hypertension: a new strategy for renin-angiotensin candidate genes. Kidney Int. 1994; 46(6):1554-6. DOI: 10.1038/ki.1994.444. View

3.
Rios C, Chu Y, Davidson B, Heistad D . Ten steps to gene therapy for cardiovascular diseases. J Lab Clin Med. 1998; 132(2):104-11. DOI: 10.1016/s0022-2143(98)90005-1. View

4.
Tsutsui M, Onoue H, Iida Y, Smith L, OBrien T, Katusic Z . Adventitia-dependent relaxations of canine basilar arteries transduced with recombinant eNOS gene. Am J Physiol. 1999; 276(6):H1846-52. DOI: 10.1152/ajpheart.1999.276.6.H1846. View

5.
Luscher T . The endothelium and cardiovascular disease--a complex relation. N Engl J Med. 1994; 330(15):1081-3. DOI: 10.1056/NEJM199404143301511. View